SCHOTT Pharma Q3 EBITDA Rises

SCHOTT Pharma AG & Co. reported third-quarter revenues of €256 million, a 1% increase (3% constant currency), with EBITDA rising 11% to €83 million, achieving a 32.4% margin. Despite this operational growth, net income remained flat at €46 million. The company provided fiscal 2025 guidance, anticipating organic revenue growth of approximately 6.0% and an EBITDA margin around 28.0%, indicating a positive outlook for top-line expansion despite a projected slight margin contraction.

Analysis

SCHOTT Pharma reported a mixed third quarter, characterized by strong operational performance offset by a stagnant bottom line. While revenues saw a modest increase of 1% to €256 million (3% at constant currency), EBITDA grew by a robust 11% to €83 million, expanding the reported EBITDA margin to a notable 32.4%. This discrepancy between top-line growth and EBITDA expansion suggests significant operational leverage or cost control during the quarter. However, this operational strength did not translate to the bottom line, as net income remained flat at €46 million and earnings per share dipped slightly to €0.30 from €0.31, indicating that factors below the EBITDA line, such as interest or tax expenses, likely eroded the gains. Looking ahead, the company's fiscal 2025 guidance projects an acceleration in organic revenue growth to approximately 6.0%, but also anticipates a significant EBITDA margin contraction to around 28.0%, tempering the outlook for future profitability.

Key Decisions for Investors

• Investors should scrutinize the drivers behind the flat net income, as the divergence from the strong 11% EBITDA growth could indicate rising financing costs or other non-operational pressures.
• The fiscal 2025 guidance presents a trade-off between accelerated revenue growth of 6.0% and a significant margin contraction to 28.0%; this warrants caution and a deeper look into the anticipated cost structure.
• Given the strong current operating margin of 32.4% versus the forward guidance of 28.0%, it may be prudent to assess whether the Q3 performance is sustainable or if the forward guidance represents a more realistic long-term profitability profile.